目次

Table of Contents

List of Tables

List of Figures
Introduction
Global Markets Direct Report Coverage
Dermatomyositis - Overview
Dermatomyositis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Dermatomyositis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Dermatomyositis - Companies Involved in Therapeutics Development
Adienne Pharma & Biotech SA
Alexion Pharmaceuticals Inc
Argenx SE
Avotres Inc
Cellular Biomedicine Group Ltd
CSL Ltd
Ermium Therapeutics SAS
Fresh Tracks Therapeutics Inc
Galapagos NV
GNI Group Ltd
Horizon Therapeutics Plc
Juventas Cell Therapy Ltd
Kezar Life Sciences Inc
NovelMed Therapeutics Inc
Paean Biotechnology Inc
Pfizer Inc
Priovant Therapeutics Inc
Santhera Pharmaceuticals Holding AG
Dermatomyositis - Drug Profiles
AVT-001 - Drug Profile
Product Description
Mechanism Of Action
begelomab - Drug Profile
Product Description
Mechanism Of Action
Biologic for Central Nervous System, Infectious Disease, Musculoskeletal Disorders and Respiratory - Drug Profile
Product Description
Mechanism Of Action
brepocitinib tosylate - Drug Profile
Product Description
Mechanism Of Action
CNCT-19 - Drug Profile
Product Description
Mechanism Of Action
CXCR4 biased agonist - Drug Profile
Product Description
Mechanism Of Action
daxdilimab - Drug Profile
Product Description
Mechanism Of Action
efgartigimod alfa - Drug Profile
Product Description
Mechanism Of Action
FRTX-10 - Drug Profile
Product Description
Mechanism Of Action
gefurulimab - Drug Profile
Product Description
Mechanism Of Action
GLPG-3667 - Drug Profile
Product Description
Mechanism Of Action
immune globulin (human) - Drug Profile
Product Description
Mechanism Of Action
Monoclonal Antibodies for Dermatomyositis - Drug Profile
Product Description
Mechanism Of Action
ONX-0914 - Drug Profile
Product Description
Mechanism Of Action
PF-06823859 - Drug Profile
Product Description
Mechanism Of Action
pirfenidone - Drug Profile
Product Description
Mechanism Of Action
PN-101 - Drug Profile
Product Description
Mechanism Of Action
ravulizumab LA - Drug Profile
Product Description
Mechanism Of Action
RD-1301 - Drug Profile
Product Description
Mechanism Of Action
tofacitinib citrate ER - Drug Profile
Product Description
Mechanism Of Action
vamorolone - Drug Profile
Product Description
Mechanism Of Action
zetomipzomib - Drug Profile
Product Description
Mechanism Of Action
Dermatomyositis - Dormant Projects
Dermatomyositis - Discontinued Products
Dermatomyositis - Product Development Milestones
Featured News & Press Releases
May 03, 2022: Kezar announces topline results from PRESIDIO trial of zetomipzomib for the treatment of dermatomyositis and polymyositis
Aug 23, 2021: Kezar Life Sciences announces completion of enrollment of its Phase 2 PRESIDIO clinical trial of KZR-616 in polymyositis and dermatomyositis
May 26, 2021: Kezar Life Sciences to host virtual MISSION phase 1b data update call at EULAR 2021
Nov 05, 2020: Kezar highlights broad therapeutic potential of KZR-616 during ACR Convergence 2020
Oct 23, 2020: Kezar Life Sciences announces Orphan Drug Designations for KZR-616 for the treatment of polymyositis and dermatomyositis
Sep 10, 2020: Kezar Life Sciences to present at The Myositis Association International Annual Patient Conference and the Pan-American Congress of Rheumatology
Sep 09, 2020: Avotres received the approval letter from the IRB to initiate human ex vivo studies of AVT001
Jun 06, 2018: GNI Group Initiates Etuary Phase III Trial in China for CTD-ILD
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Dermatomyositis, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Dermatomyositis - Pipeline by Adienne Pharma & Biotech SA, 2022
Dermatomyositis - Pipeline by Alexion Pharmaceuticals Inc, 2022
Dermatomyositis - Pipeline by Argenx SE, 2022
Dermatomyositis - Pipeline by Avotres Inc, 2022
Dermatomyositis - Pipeline by Cellular Biomedicine Group Ltd, 2022
Dermatomyositis - Pipeline by CSL Ltd, 2022
Dermatomyositis - Pipeline by Ermium Therapeutics SAS, 2022
Dermatomyositis - Pipeline by Fresh Tracks Therapeutics Inc, 2022
Dermatomyositis - Pipeline by Galapagos NV, 2022
Dermatomyositis - Pipeline by GNI Group Ltd, 2022
Dermatomyositis - Pipeline by Horizon Therapeutics Plc, 2022
Dermatomyositis - Pipeline by Juventas Cell Therapy Ltd, 2022
Dermatomyositis - Pipeline by Kezar Life Sciences Inc, 2022
Dermatomyositis - Pipeline by NovelMed Therapeutics Inc, 2022
Dermatomyositis - Pipeline by Paean Biotechnology Inc, 2022
Dermatomyositis - Pipeline by Pfizer Inc, 2022
Dermatomyositis - Pipeline by Priovant Therapeutics Inc, 2022
Dermatomyositis - Pipeline by Santhera Pharmaceuticals Holding AG, 2022
Dermatomyositis - Dormant Projects, 2022
Dermatomyositis - Dormant Projects, 2022 (Contd..1)
Dermatomyositis - Discontinued Products, 2022

List of Figures
Number of Products under Development for Dermatomyositis, 2022
Number of Products under Development by Companies, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Top 10 Routes of Administration, 2022
Number of Products by Stage and Top 10 Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022